Literature DB >> 16243531

Histomorphometric analysis of glucocorticoid-induced osteoporosis.

L Dalle Carbonare1, F Bertoldo, M T Valenti, S Zenari, M Zanatta, S Sella, S Giannini, V Lo Cascio.   

Abstract

Bone histomorphometry or quantitative histology consists of counting or measuring tissue components: cells, extracellular constituents and microarchitecture. Bone histomorphometry is the only method that allows the measurement of mineralization rate and the study of bone formation at three levels: cell, remodeling unit and tissue levels. It is a useful tool to explain the pathogenesis and cellular mechanisms of different metabolic bone diseases such as glucocorticoid-induced osteoporosis (GIO). Glucocorticoids (GC) affect calcium and bone metabolism at every level, but the main effect is the osteoblastic dysfunction. Concerning the bone formation, some histomorphometric studies have shown a depressed osteoblastic activity at a cell, bone remodeling unit, and tissue levels. In addition, there is evidence of a shortening of the period in which the osteoblasts work actively forming the bone matrix. This latter effect seems to occur after high cumulative doses of GC. With regard to the resorption, the results are still debated, but histomorphometric parameters seem to be increased in the majority of studies, at least in the first period of the GC treatment. From a structural point of view, GC seem to induce a thinning of the trabeculae without their perforation, which occurs only after high cumulative doses. Anti-resorptive treatments, such as bisphosphonates, are able to counteract the negative effects of GC on bone. In particular, along with their active working period, they prolong the lifespan of osteoblasts and osteocytes. In addition, the anti-resorptive treatments seem to extend the time for secondary mineralization through a reduction of the Activation Frequency. The latter is an intriguing mechanism of bisphosphonates in GIO that needs further ad hoc investigations.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16243531     DOI: 10.1016/j.micron.2005.07.009

Source DB:  PubMed          Journal:  Micron        ISSN: 0968-4328            Impact factor:   2.251


  22 in total

1.  Ultrastructural characteristics of glucocorticoid-induced osteoporosis.

Authors:  B Bouvard; M Audran; E Legrand; D Chappard
Journal:  Osteoporos Int       Date:  2009-06       Impact factor: 4.507

2.  Effect of renal function on skeletal health in primary hyperparathyroidism.

Authors:  Marcella D Walker; David W Dempster; Donald J McMahon; Julia Udesky; Elizabeth Shane; John P Bilezikian; Shonni J Silverberg
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

Review 3.  From histology to micro-CT: Measuring and modeling resorption cavities and their relation to bone competence.

Authors:  Jef Vanderoost; G Harry van Lenthe
Journal:  World J Radiol       Date:  2014-09-28

Review 4.  Protecting Bone Health in Pediatric Rheumatic Diseases: Pharmacological Considerations.

Authors:  Yujuan Zhang; Diana Milojevic
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

5.  Skeletal health of children and adolescents with inflammatory bowel disease.

Authors:  Helen Pappa; Meena Thayu; Francisco Sylvester; Mary Leonard; Babette Zemel; Catherine Gordon
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-07       Impact factor: 2.839

6.  An unusual case of hypercortisolism with multiple weight-bearing bone fractures.

Authors:  Georgios Papadakis; Brigitte Uebelhart; Michel Goumaz; Sophie Zawadynski; Rene Rizzoli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

Review 7.  Skeletal involvement in adult patients with endogenous hypercortisolism.

Authors:  I Chiodini; M Torlontano; V Carnevale; V Trischitta; A Scillitani
Journal:  J Endocrinol Invest       Date:  2008-03       Impact factor: 4.256

Review 8.  Medication-induced osteoporosis.

Authors:  Meng-Yi Weng; Nancy E Lane
Journal:  Curr Osteoporos Rep       Date:  2007-12       Impact factor: 5.096

Review 9.  Clinical perspectives on bone quality in osteoporosis: effects of drug therapy.

Authors:  Angelo A Licata
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

Review 10.  Long-term therapy in COPD: any evidence of adverse effect on bone?

Authors:  Arnulf Langhammer; Siri Forsmo; Unni Syversen
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-10-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.